Pfizer is in talks to grant a license that will allow Chinese domestic drugmakers to manufacture and distribute a generic version of COVID-19 antiviral drug Paxlovid in China, three sources told Reuters. China’s National Medical Products Administration, or NMPA, has been leading the talks with Pfizer since late last month, one of the sources told Reuters’ Julie Zhu and Kevin Huang. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE:
- Pfizer: FDA accepts for priority review sBLA for 20vPnC
- Morgan Stanley sees Moderna’s phase 3 RSV vaccine data as catalyst-driven idea
- 3D Systems appoints Bruce to Medical Advisory Board
- BioMarin price target raised to $200, added to ‘US 1 List’ at BofA
- Pfizer downgraded to Neutral at BofA on COVID-19 uncertainty